Inhibition of olanzapine-induced weight gain by the retinoid analog AM-80

Pharmacopsychiatry

Volumn 46, Issue 7, 2013, Pages 267-273

  Richards, M ^a   Chiba, S ^b   Ninomiya, M ^b   Wakabayasi, C ^b   Kunugi, H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

AM 80; metabolic syndrome; obesity; olanzapine; retinoid

Indexed keywords

ADIPONECTIN; LEPTIN; OLANZAPINE; TAMIBAROTENE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; DRUG INDUCED DISEASE; FEMALE; FLUID INTAKE; FOOD INTAKE; NONHUMAN; OBESITY; OLANZAPINE INDUCED WEIGHT GAIN; ORGAN WEIGHT; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; WEIGHT GAIN;

ADIPONECTIN; ADIPOSITY; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZOATES; BENZODIAZEPINES; BODY WEIGHT; DRINKING; EATING; FEMALE; LEPTIN; MOTOR ACTIVITY; RATS; RETINOIDS; SENSORY GATING; TETRAHYDRONAPHTHALENES; WEIGHT GAIN;

EID: 84887841817     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0033-1354406     Document Type: Article

References (64)

1. Freedman R. Schizophrenia. N Engl J Med: 2003; 349 1738 1749 (Pubitemid 37315012)
2. Allison D. B., Mentore J. L., Heo M. et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry: 1999; 156 1686 1696 (Pubitemid 29517559)
3. Henderson D. C. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs: 2002; 16 77 89 (Pubitemid 34155205)
4. Zimmermann U., Kraus T., Himmerich H. et al. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res: 2003; 37 193 220 (Pubitemid 36321747)
5. Holt R. I., Peveler R. C., Byrne C. D. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med: 2004; 21 515 523 (Pubitemid 38746268)
6. Goudie A. J., Cooper G. D., Halford J. C. Antipsychotic-induced weight gain. Diabetes Obes Metab: 2005; 7 478 487 (Pubitemid 41150421)
7. Schotte A., Janssen P. F., Gommeren W. et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl): 1996; 124 57 73 (Pubitemid 26112775)
8. Casey D. E. The relationship of pharmacology to side effects. J Clin Psychiatry: 1997; 58 10 55 62 (Pubitemid 27333182)
9. Hale A. S. Olanzapine. Br J Hosp Med: 1997; 58 442 445
10. Green B. Focus on olanzapine. Curr Med Res Opin: 1999; 15 79 85 (Pubitemid 29306738)
11. Wirshing D. A., Wirshing W. C., Kysar L. et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry: 1999; 60 358 363 (Pubitemid 29289721)
12. Graham K. A., Perkins D. O., Edwards L. J. et al. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry: 2005; 162 118 123 (Pubitemid 40095680)
13. Henderson D. C., Cagliero E., Gray C. et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry: 2000; 157 975 981 (Pubitemid 30412350)
14. Baptista T., Contreras Q., Teneud L. et al. Mechanism of the neuroleptic-induced obesity in female rats. Prog Neuropsychopharmacol Biol Psychiatry: 1998; 22 187 198 (Pubitemid 28096437)
15. Baptista T., Araujo de Baptista E., Ying Kin N. M. et al. Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Res: 2002; 957 144 151 (Pubitemid 35346582)
16. Goudie A. J., Smith J. A., Halford J. C. Characterization of olanzapine-induced weight gain in rats. J Psychopharmacol: 2002; 16 291 296 (Pubitemid 35470572)
17. Kaur G., Kulkarni S. K. Studies on modulation of feeding behavior by atypical antipsychotics in female mice. Prog Neuropsychopharmacol Biol Psychiatry: 2002; 26 277 285 (Pubitemid 34038054)
18. Arjona A. A., Zhang S. X., Adamson B. et al. An animal model of antipsychotic-induced weight gain. Behav Brain Res: 2004; 152 121 127 (Pubitemid 38597070)
19. Kirk S. L., Neill J. C., Jones D. N. et al. Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. Eur J Pharmacol: 2004; 505 253 254 (Pubitemid 39535699)
20. Cooper G. D., Pickavance L. C., Wilding J. P. et al. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl): 2005; 181 80 89 (Pubitemid 41440918)
21. Berry D. C., Noy N. All- trans -retinoic acid represses obesity and insulin resistance by activating both peroxisome proliferation-activated receptor beta/delta and retinoic acid receptor. Mol Cell Biol: 2009; 29 3286 3296
22. Miwako I., Kagechika H. Tamibarotene. Drugs Today (Barc): 2007; 43 563 568 (Pubitemid 47529739)
23. Takeuchi M. Clinical experience with a new synthetic retinoid, tamibarotene (Am-80) for relapsed or refractory acute promyelocytic leukemia. Gan To Kagaku Ryoho: 2006; 33 397 401
24. Kamei Y., Kawada T., Mizukami J. et al. The prevention of adipose differentiation of 3T3-L1 cells caused by retinoic acid is elicited through retinoic acid receptor alpha. Life Sci: 1994; 55 PL307 PL312 (Pubitemid 124015897)
25. Fell M. J., Marshall K. M., Williams J. et al. Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharmacol: 2004; 18 149 155 (Pubitemid 38954901)
26. Fatemi S. H., Reutiman T. J., Folsom T. D. et al. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology: 2006; 31 1888 1899
27. Bakshi V. P., Geyer M. A. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology (Berl): 1995; 122 198 201 (Pubitemid 26019155)
28. Depoortere R., Perrault G., Sanger D. J. Some, but not all, antipsychotic drugs potentiate a low level of prepulse inhibition shown by rats of the Wistar strain. Behav Pharmacol: 1997; 8 64 72
29. Yamada S., Harano M., Annoh N. et al. Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats. Biol Psychiatry: 1999; 46 832 838 (Pubitemid 29460911)
30. Arnt J. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol: 1995; 283 55 62
31. El-Mallakh R. S., Decker S., Morris M. et al. Efficacy of olanzapine and haloperidol in an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry: 2006; 30 1261 1264 (Pubitemid 44216066)
32. Chiba S., Numakawa T., Ninomiya M. et al. Chronic restraint stress causes anxiety- and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry: 2012; 39 112 119
33. Wakabayashi C., Numakawa T., Ninomiya M. et al. Behavioral and molecular evidence for psychotropic effects in L-theanine. Psychopharmacology (Berl): 2012; 219 1099 1109
34. Daniels S. R. Abnormal weight gain and weight management: are carbohydrates the enemy? J Pediatr: 2003; 142 225 227 (Pubitemid 36337998)
35. Moore N. A., Leander J. D., Benvenga M. J. et al. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry: 1997; 58 10 37 44 (Pubitemid 27333179)
36. Pouzet B., Mow T., Kreilgaard M. et al. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav: 2003; 75 133 140 (Pubitemid 36577588)
37. Basson B. R., Kinon B. J., Taylor C. C. et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry: 2001; 62 231 238 (Pubitemid 32428761)
38. Baptista T., Zarate J., Joober R. et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets: 2004; 5 279 299 (Pubitemid 38372313)
39. Haupt D. W., Luber A., Maeda J. et al. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology: 2005; 30 184 191 (Pubitemid 40024412)
40. Richards A. A., Hickman I. J., Wang A. Y. et al. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. J Clin Psychopharmacol: 2006; 26 232 237 (Pubitemid 43804614)
41. Kraus T., Haack M., Schuld A. et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry: 1999; 156 312 314 (Pubitemid 29077125)
42. Melkersson K. I., Hulting A. L., Brismar K. E. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry: 2000; 61 742 749
43. Atmaca M., Kuloglu M., Tezcan E. et al. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res: 2003; 60 99 100 (Pubitemid 36015794)
44. McIntyre R. S. Antipsychotic drugs and diabetes. CMAJ: 2003; 168 673
45. Cooper G. D., Pickavance L. C., Wilding J. P. et al. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol: 2007; 21 405 413 (Pubitemid 47077303)
46. Fell M. J., Anjum N., Dickinson K. et al. The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology (Berl): 2007; 194 221 231 (Pubitemid 47457949)
47. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab: 2003; 14 137 145 (Pubitemid 36733912)
48. Goldfine A. B., Kahn C. R. Adiponectin: linking the fat cell to insulin sensitivity. Lancet: 2003; 362 1431 1432 (Pubitemid 37352876)
49. Hotta K., Funahashi T., Arita Y. et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol: 2000; 20 1595 1599 (Pubitemid 30353893)
50. Asayama K., Hayashibe H., Dobashi K. et al. Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obes Res: 2003; 11 1072 1079 (Pubitemid 41151584)
51. Togo T., Kojima K., Shoji M. et al. Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study. Int Clin Psychopharmacol: 2004; 19 37 40 (Pubitemid 38114623)
52. Han M., Deng C., Burne T. H. et al. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology: 2008; 33 569 580
53. Terry A. V. Jr, Warner S. E., Vandenhuerk L. et al. Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats. Neuroscience: 2008; 156 1005 1016
54. Kozlovskii V. L., Kenunen O. G., Khrabrova A. V. Experimental study of the effects of citalopram, olanzapine, and their combinations in tests for antipsychotic, antidepressant and anxiolytic activities of drugs. Eksp Klin Farmakol: 2008; 71 6 10
55. Ogilvie K. M., Saladin R., Nagy T. R. et al. Activation of the retinoid X receptor suppresses appetite in the rat. Endocrinology: 2004; 145 565 573 (Pubitemid 38183798)
56. Shulman A. I., Mangelsdorf D. J. Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med: 2005; 353 604 615 (Pubitemid 41138942)
57. Barish G. D., Narkar V. A., Evans R. M. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest: 2006; 116 590 597 (Pubitemid 43326863)
58. Wolf G. Retinoic acid as cause of cell proliferation or cell growth inhibition depending on activation of one of two different nuclear receptors. Nutr Rev: 2008; 66 55 59 (Pubitemid 351666662)
59. Redonnet A., Ferrand C., Bairras C. et al. Synergic effect of vitamin A and high-fat diet in adipose tissue development and nuclear receptor expression in young rats. Br J Nutr: 2008; 100 722 730
60. Murano I., Morroni M., Zingaretti M. C. et al. Morphology of ferret subcutaneous adipose tissue after 6-month daily supplementation with oral beta-carotene. Biochim Biophys Acta: 2005; 1740 305 312 (Pubitemid 40798238)
61. Krupková M., Janků M., Liska F. et al. Pharmacogenetic model of retinoic acid-induced dyslipidemia and insulin resistance. Pharmacogenomics: 2009; 10 1915 1927
62. Bonet M. L., Ribot J., Palou A. Lipid metabolism in mammalian tissues and its control by retinoic acid. Biochim Biophys Acta: 2012; 1821 177 189
63. Bonet M-L, Ribot J., Felipe F. et al. Vitamin A and the regulation of fat reserves. Cell Mol Life Sci: 2003; 60 1311 1321 (Pubitemid 36900515)
64. Tobita T., Takeshita A., Kitamura K. et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all- trans -retinoic acid. Blood: 1997; 90 967 973 (Pubitemid 27314129)